BioTalk with Rich Bendis Podcast

Luis Alvarez and Rich JPGHow will protein engineering unleash a new era of therapeutic possibilities for BioHealth and the BioHealth Capital Region? Join us on this episode of BioTalk with Rich Bendis as Rich chats with Dr. Luis Alvarez, Founder & CEO of Theradaptive, who is at the forefront of protein engineering technology. Learn about Theradaptive’s ingenious approach to overcoming the challenges of naturally occurring proteins, elevating the efficacy and safety of therapeutics through precision-targeted delivery, and mitigating off-target side effects. From spinal fusion and orthopedics to soft tissue repair and targeted chemotherapeutics, Theradaptive’s breakthrough technology is set to transform the lives of millions grappling with debilitating conditions linked to loss of tissue function. Be part of the conversation that’s unlocking a world of untapped potential in the convergence of protein engineering and therapeutic discovery. Listen now here or via your favorite podcasting platforms:

A graduate of West Point, Dr. Luis Alvarez served in the U.S. Army for 20 years. Following a combat tour and seeing fellow servicemembers forced to undergo delayed amputations due to tissue damage, he was motivated to pursue a Ph.D. in biological engineering at MIT, where he was a Hertz Foundation Fellow. Dr. Alvarez founded Theradaptive following his time in the Army, using what he learned from his research to create a platform that can now deliver biologics in a highly targeted way. Previously, he was the founding deputy director of the U.S. Department of Defense’s Regenerative Medicine Program Office as well as lead for the DoD’s $720 million nerve agent pharmaceutical countermeasures program. As CEO and co-founder, Dr. Alvarez has seen the Theradaptive team grow from two to 32 people. The FDA granted the company three breakthrough designations for various spine indications, accelerating the process of reaching approval.

Click here for the transcript